NCCN Medical Education Disclosure Policy
It is the policy of NCCN that every 12 months, all faculty, moderators, activity planners and all internal planning staff participating in NCCN continuing education activities are expected to disclose any financial relationships with a commercial interest as defined by the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support. In addition, all faculty presentations have been reviewed for adherence to the ACCME’s Standards for Commercial Support (the provider develops activities/educational interventions independent of commercial interests [SCS 1, 2 and 6] by experts on the topics). 

Per the ACCME Standards for Commercial Support, individuals who do not disclose relevant financial relationships will be disqualified from involvement in the CE activity as a content developer, planner, or presenter. A complete list of individuals’ relationships with external entities is available upon request.

Definitions  
NCCN continuing education considers financial relationships to create a “conflict of interest” when an individual has both a financial relationship with a commercial interest and the opportunity to affect CE content about the products or services of a commercial interest with which he/she and/or a spouse or partner has a financial relationship.

NCCN continuing education considers “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that create a conflict of interest. NCCN does not set a minimal dollar amount for relationships to be significant. Inherent in any amount is the incentive to maintain or increase the value of the relationship. 

Faculty Disclaimers  
All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation for the tasks and methods of delivery.

Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling.

The NCCN staff listed below discloses no relevant financial relationships:
Kerrin M. Rosenthal, MA; Kimberly Callan, MS; Genevieve Emberger Hartzman, MA; Erin Hesler; Kristina M. Gregory, RN, MSN, OCN; Rashmi Kumar, PhD; Karen Kanefield; and Kathy Smith.

Individuals Who Provided Content Development and/or Authorship Assistance:
Matthew P. Goetz, MD, Panel Member, has disclosed that he has served as a scientific advisor for Biotheranostics, Eli Lilly and Company, and Sermonix Pharmaceuticals; has received grant/research support from Eli Lilly and Company and Pfizer Inc.; and has received consulting fees/honoraria from Genomic Health, Inc., Biovica International AB, and Sermonix Pharmaceuticals.
William J. Gradishar, MD, Panel Chair, has disclosed that he has no relevant financial relationships.
Jame Abraham, MD, Panel Member, has disclosed that he has no relevant financial relationships.
Harold J. Burstein, MD, PhD, Panel Member, has disclosed that he has no relevant financial relationships.
Chau Dang, MD, Panel Member, has disclosed that she has received grant/research support from Roche/Genentech and Puma Biotechnology, Inc.
Lori J. Goldstein, MD, Panel Member, has disclosed that she has served as a scientific advisor for Amgen Inc., AstraZeneca Pharmaceuticals LP, Daiichi Sankyo, Inc., Eisai Inc., Genomic Health, Inc., and Merck & Co., Inc.
Steven J. Isakoff, MD, PhD, Panel Member, has disclosed that he receives grant/research support from AbbVie, Inc., AstraZeneca Pharmaceuticals LP, Genentech, Inc., Merck & Co., Inc., OncoPep, Inc., and PharmaMar. He also has received consulting fees/honoraria from Genentech, Inc., Immunomedics, Inc., Myriad Genetic Laboratories, Inc., Hengrui Therapeutics, Inc., Mylan, and Puma Biotechnology, Inc.
Meena S. Moran, MD, Panel Member, has disclosed that she has no relevant financial relationships.
Hope S. Rugo, MD, Panel Member, has disclosed that she receives grant/research support from Pfizer Inc.; Merck & Co., Inc.; Novartis Pharmaceuticals; Eli Lilly and Company; OBI Pharma; Genentech, Inc.; Odonate Therapeutics, Inc.; Daiichi Sankyo, Inc.; Eisai Inc.; Seattle Genetics, Inc.; and MacroGenics, Inc. She also receives consulting fees/honoraria from Eli Lilly and Company, Mylan, Pfizer Inc., Amgen Inc., Merck & Co., Inc., and Puma Biotechnology, Inc.
Karen Lisa Smith, MD, MPH, Panel Member, has disclosed that she has received grant/research support from Pfizer Inc. and Puma Biotechnology, Inc., and that her spouse has equity interest/stock options in AbbVie Inc. and Abbott Laboratories.
Hatem Soliman, MD, Panel Member, has disclosed that he has served as a consultant for Eli Lilly and Company, Pfizer Inc., AstraZeneca Pharmaceuticals LP, Novartis AG, Puma Biotechnology, Inc., and Celgene Corporation.
Melinda L. Telli, MD, Panel Member, has disclosed that she has served as a scientific advisor for Celldex Therapeutics; Genentech, Inc.; Immunomedics, Inc.; Merck & Co., Inc.; Aduro BioTech, Inc.; Pfizer Inc.; and Tesaro, Inc.
John H. Ward, MD, Panel Member, has disclosed that he has no relevant financial relationships.
Dorothy A. Shead, MS, Director, Patient Information Operations, NCCN, has disclosed that she has no relevant financial relationships.